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Abstract
Autoinhibition of the Rho guanine nucleotide exchange factor ASEF is relieved by interaction with
the APC tumor suppressor. Here we show that binding of the armadillo repeats of APC to a ‘core
APC-binding’ (CAB) motif within ASEF, or truncation of the SH3 domain of ASEF, relieves
autoinhibition, allowing the specific activation of CDC42. Structural determination of autoinhibited
ASEF reveals that the SH3 domain forms an extensive interface with the catalytic DH and PH
domains to obstruct binding and activation of CDC42, and the CAB motif is positioned adjacent to
the SH3 domain to facilitate activation by APC. In colorectal cancer cell lines, full-length, but not
truncated, APC activates CDC42 in an ASEF-dependent manner to suppress anchorage-independent
growth. We therefore propose a model in which ASEF acts as a tumor suppressor when activated by
APC and inactivation of ASEF by mutation or APC truncation promotes tumorigenesis.
The adenomatous polyposis coli (APC) protein is a negative regulator of the Wnt signaling
pathway and promotes the phosphorylation and degradation of β-catenin1. The majority of
colorectal cancers (CRCs) harbor C-terminally truncated forms of APC that retain the N-
terminal coiled-coil domain and the highly conserved armadillo repeat region (APCArm)2 and
are unable to regulate the degradation of β-catenin3. Recent studies suggest that APC regulates
cytoskeletal dynamics to influence cellular migration, cell division, polarization and adhesion,
and it seems increasingly likely that deregulated cytoskeletal dynamics, together with
enhancement of transcription by β-catenin, potentiate tumor formation and progression upon
APC truncation.
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APC may regulate cytoskeletal networks by binding to microtubules and to proteins implicated
in reorganization of the actin cytoskeleton, such as the Rho effectors mDia and IQGAP1 and
the Rho guanine nucleotide exchange factor (RhoGEF) ‘APC-stimulated guanine nucleotide
exchange factor’ (ASEF, also called ARHGEF4)4. ASEF is a Dbl-family GEF that contains
an Src-homology-3 (SH3) domain followed by the Dbl-homology (DH) and pleckstrin-
homology (PH) domains characteristic of Dbl-family GEFs that specifically activate members
of the Rho family of GTPases. DH and PH domains in Dbl proteins catalyze the exchange of
GDP for GTP in Rho GTPases, allowing them to signal to downstream effectors5. ASEF is
homologous to the Dbl proteins collybistin (also called PEM2) and SPATA13 (also called
ASEF2), both of which have been shown to activate specifically CDC42 and not other Rho-
family GTPases6,7.
Previous data suggest that ASEF exists in an autoinhibited form and is activated upon binding
of APCArm to the region termed the APC-binding region (ABR)8. Binding of APCArm to the
ABR stimulates activation of the Rho GTPase RAC1 by ASEF. Furthermore, truncation of the
ABR is sufficient to relieve autoinhibition, rendering ASEF constitutively active. In addition,
truncated, but not wild-type, APC has been shown to efficiently activate ASEF to promote
cancer cell migration9.
In this study, we wished to delineate the molecular mechanism by which APC relieves
autoinhibition of ASEF to stimulate its GEF activity and to assess the contribution of ASEF
to CRC tumorigenesis. To our surprise, and in contrast to previous reports, we found that ASEF
specifically activated CDC42, but not RAC1 or other Rho GTPases, in vitro and in vivo.
Furthermore, whereas binding of APCArm to ASEF stimulated robust exchange activity on
CDC42, truncation of the ABR of ASEF did not activate ASEF. Instead, truncation of the SH3
domain was required to activate the exchange activity of ASEF toward CDC42. Indeed, a 2.25-
Å -resolution structure of an autoinhibited form of ASEF revealed that the SH3 domain of
ASEF forms a tight and extensive interface with both the DH and PH domains to effectively
block access of CDC42 to the GTPase-binding site. Also in contrast to previous data9, we show
that ASEF functions downstream of full-length APC, but not its truncated form, to activate
CDC42. Silencing the expression of ASEF in CRC cell lines expressing wild-type, but not
truncated, APC resulted in a considerable growth advantage for these cells. Finally, we show
that a recently identified mutation in ASEF found in breast cancer abolishes the GEF activity
of ASEF. These data suggest that ASEF is a tumor suppressor that links full-length APC to
CDC42 and that its inactivation, by mutation of either APC or ASEF, promotes cancer
progression.
RESULTS
ASEF is a RhoGEF specific for CDC42
Previous structural analyses of RhoGEFs bound to their cognate Rho GTPases provide
guidelines for predicting the GTPase specificities of DH domains on the basis of their primary
sequences10–14. DH domains of RAC1-specific GEFs such as Tiam1 and TRIO typically have
isoleucine (Ile1187 in Tiam1) in a position where DH domains of CDC42-specific GEFs, such
as Intersectin (ITSN) and PEM2/collybistin, have leucine (Leu1376 in ITSN) (Fig. 1a). ASEF
features a leucine (Leu421) at the position equivalent to Ile1187 of Tiam1, suggesting that
ASEF might be specific for CDC42. Indeed, a fragment of ASEF encompassing the DH and
PH domains catalyzed nucleotide exchange specifically on CDC42 but not RAC1 or RHOA
(Fig. 1b). Furthermore, ASEF showed no exchange activity toward other Rho family members,
including RHOB, RHOC, RAC2, RAC3, RHOG, TC10, TCL and RHOF (Supplementary Fig.
1 online and data not shown). Moreover, an L421I substitution in the DH/PH fragment of ASEF
conferred the capacity to activate RAC1 at the expense of CDC42 (Fig. 1c). These data confirm
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the importance of Leu421 of ASEF in dictating specificity toward CDC42 while prohibiting
RAC1 activation.
We assessed the in vivo specificity of ASEF for Rho GTPases by monitoring effects of ASEF
expression on the actin cytoskeleton, which undergoes distinct morphological rearrangements
in response to the activation of different Rho GTPases15. Overexpression of a DH/PH fragment
of ASEF fused to yellow fluorescent protein (YFP–ASEF DH/PH) in NIH3T3 mouse
fibroblasts resulted in spindle-like projections rich in F-actin, similar to the filopodia induced
by activated CDC42 fused to green fluorescent protein (GFP–CDC42 61L) but not the lamella
induced by activated RAC1 fused to GFP (GFP–RAC1 61L) (Fig. 2a). The isolated CRIB
domain from the CDC42-specific effector N-WASP (N-WASP CRIB) binds to, and blocks
signaling downstream of, active CDC42 but not RAC1 in a dominant-negative fashion16.
Coexpression of N-WASP CRIB with either GFP–CDC42 61L or YFP–ASEF DH/PH
effectively suppressed the formation of filopodia. In contrast, N-WASP CRIB did not block
lamella formation induced by RAC1 (Fig. 2b). Therefore, in contrast to its original
characterization, ASEF specifically activates CDC42 and not other Rho GTPases in vitro and
in vivo.
ASEF is autoinhibited by the SH3 domain
The primary ASEF isoform expressed in human tissues is encoded by ARHGEF4 (ref. 17; here
called ASEF). This isoform contains sequences on the N-terminal side of the ABR domain that
are distinct from those encoded in the gene that was originally cloned8.We therefore used this
predominant isoform throughout the experiments below as full-length ASEF (residues 1–690;
see Supplementary Methods.online).
To map regions within ASEF necessary for the autoinhibition of exchange activity, a series of
truncated forms of ASEF (Fig. 3a) were tested for their capacity to activate CDC42 in vitro.
To our surprise, and in contrast to previous reports8,9, truncation of the N terminus alone
(ΔN) or together with part or all of the ABR (ΔABR1–ΔABR4) did not elicit guanine nucleotide
exchange on CDC42 (Fig. 3b). However, further N-terminal truncation to remove the SH3
domain of ASEF (DH/PH) greatly increased the exchange activity of ASEF toward CDC42.
We found similar results upon overexpression of N-terminally truncated forms of ASEF in
NIH3T3 cells (Fig. 3c). That is, full-length ASEF, as well as N-terminally truncated ASEF
lacking its ABR but retaining its SH3 domain (ΔABR4), were incapable of producing CDC42-
like filopodia. In contrast, ASEF DH/PH, which lacks both the ABR and SH3 domains, induced
filopodia formation (Fig. 2a and Fig. 3c). Therefore, the SH3 domain is fully responsible for
autoinhibition of the exchange activity of ASEF in vitro and in vivo, and regions on the N-
terminal side of the SH3 domain, including the ABR, are irrelevant for this autoinhibition.
Attempts to measure increased CDC42-GTP in cells expressing ASEF by affinity precipitation
assays were unsuccessful owing to persistent elevated CDC42-GTP levels in the absence of
serum (data not shown, and refs. 18,19).
Identification of the core APC-binding motif
The ABR is a 53-residue region of ASEF necessary for interaction with the armadillo repeats
of APC. The ABR is conserved among ASEF orthologs and is approximately 50% identical
in sequence to the ABR of ASEF2. Collybistin does not contain an ABR region6,20 and
therefore is not regulated by APC (data not shown).
To identify specific functional determinants within the ABR, N-terminally truncated forms of
ASEF were tested for their capacity to activate CDC42 in the presence of the full armadillo
repeat array of APC. As expected, incubation of ASEF ΔN with APCArm stimulated the guanine
nucleotide exchange activity of ASEF toward CDC42, whereas ASEF ΔABR4, which
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completely lacks the ABR, was not stimulated by APCArm (Fig. 4a). Furthermore, ASEF
ΔABR1, ASEF ΔABR2 and ASEF ΔABR3 were activated by APCArm similarly to ASEF
ΔN. These results indicate that the minimal ABR sequence (residues 183–193) encompassed
in ASEF ΔABR3 and lacking in ASEF ΔABR4 is absolutely required for interaction with
APCArm and concomitant activation of CDC42 by ASEF. This region, which we term the core
ATP-binding (CAB) motif, is immediately adjacent to the SH3 domain on the N-terminal side
and is strictly conserved in ASEF2 (Fig. 4b).
The ASEF-related homolog ASEF2 shows high sequence conservation with ASEF, and, like
ASEF, its GEF activity is stimulated by APCArm. However, APCArm has been reported to
interact with the SH3 domain and not the ABR of ASEF2 to stimulate GEF activity7. We found
that ASEF2 ΔN (containing the ABR) was robustly stimulated by APCArm to catalyze
nucleotide exchange on CDC42, whereas ASEF2 ΔABR4 (no ABR) was not (Fig. 4c).
Therefore, as with ASEF, the ABR region within ASEF2 is essential for activation of RhoGEF
catalytic function by APCArm. Given the strict conservation of the CAB motif in both ASEF
and ASEF2, it is highly likely that the CAB motif of ASEF2 is absolutely required for binding
to APC.
Full-length but not truncated APC activates ASEF
APC mutants associated with CRCs lack binding sites for microtubules and β-catenin but retain
the oligomerization domain and the highly conserved ARM repeats (residues 335–735)21 (Fig.
5a). To directly assess the capacity of APC to activate ASEF, we expressed these proteins in
COS-7 cells, where the subcellular localization of exogenous full-length or truncated forms of
APC recapitulates their endogenous localization in CRC cell lines22,23. Of note, in COS-7
cells, overexpression of activated CDC42 (GFP–CDC42 61L) results in the formation of dorsal
and peripheral membrane ruffles, whereas activated RAC1 in COS-7 cells induces peripheral
ruffles that are thicker and morphologically distinct24 (Fig. 5b). Consistent with our previous
data, activated ASEF (YFP–ASEF DH/PH) induces membrane ruffles in COS-7 cells
indistinguishable from those induced by constitutively active CDC42.
When expressed separately, both GFP-tagged APCArm and mCherry-tagged full-length (FL)
ASEF showed diffuse nuclear and cytoplasmic localization (Fig. 5c) with no obvious changes
in cell morphology compared to cells expressing mCherry alone. However, coexpression of
GFP-APCArm and mCherry–FL ASEF resulted in their colocalization in prominent peripheral
(arrow) and dorsal (arrow-head) ruffles. Colocalization and ruffle formation were abrogated
if the expressed APCArm protein harbored a point mutation (N507K; Fig. 5c) previously shown
to prevent interaction of APC with ASEF (Supplementary Fig. 2 online and ref. 25).
Furthermore, consistent with our in vitro data, concomitant colocalization and ruffle formation
were lost when APCArm was coexpressed with a version of ASEF lacking the ABR (mCherry–
ASEF ΔABR4).
Nonsense mutation of codon 1061 results in a common germline truncation of APC associated
with CRCs2 (Fig. 5a). In agreement with published reports22,26, exogenously expressed GFP-
tagged full-length APC localized to a filamentous meshwork likely to be the microtubule
cytoskeleton, whereas a similar construct of APC terminating at position 1061 (APC 1061)
was distributed diffusely and in intermittent dense puncta throughout the cytoplasm (Fig. 5d).
Notably, when GFP–FL APC was coexpressed with mCherry–FL ASEF, the two proteins
colocalized in dorsal ruffles and in puncta close to the plasma membrane (Fig. 5d, inset),
suggesting that they interact to activate CDC42. Furthermore, the N507K mutation in the
context of full-length APC (GFP–FL APC N507K) disrupted colocalization with mCherry–
FL ASEF, and no dorsal ruffles were observed. Contrary to the previous suggestion that
truncated APC activates ASEF in vivo9, GFP–APC 1061 did not colocalize with mCherry–FL
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ASEF or promote membrane ruffling. Therefore, we conclude that full-length APC, but not a
form terminating at residue 1061, readily stimulates ASEF in COS-7 cells.
Structure of autoinhibited ASEF
ASEF ΔABR2 is a minimal fragment of ASEF that is completely inhibited in the absence of
APC (Fig. 3b) yet fully activated by APCArm (Fig. 4a). To elucidate the structural basis for the
autoinhibition of ASEF and its related activation by APC, we determined a high-resolution
structure of ASEF ΔABR2 (residues 170–632) by X-ray crystallography (Supplementary Fig.
3 online).
At the heart of the structure is the SH3 domain, which organizes the inhibited conformation of
ASEF (Fig. 6a). The five β-strands of the ASEF SH3 domain form a β-barrel similar to other
SH3 domains. Other common features include the RT loop (between β1 and β2) and the n-Src
loop (between β2 and β3), which typically engage peptide ligands containing multiple
prolines27, as well as a short 310-helix separating β4 and β5. Capping the end of the β-barrel
is the CAB motif, which forms an extended region (residues 183–186) and a short α-helix
(αCAB, residues 187–193). αCAB within the CAB motif primarily interacts with the SH3
domain through contacts with β2 and the n-Src loop. Residues Glu183, Leu185, Glu189 and
Asp193 within the CAB motif are solvent exposed and evolutionarily conserved among ASEF
homologs, indicating that they may be important for interaction with APC.
The SH3 domain forms an extensive interface primarily with the DH domain, but major
interactions also include the PH domain. Of the 4,170 Å2 of solvent-accessible area on the
surface of the ASEF SH3 domain, 1170 Å2 are buried through interaction with the DH and PH
domains. Elements from the SH3 domain, including β1, the RT loop, the 310-helix, β5 and the
extended region on the C-terminal side of β5, form multiple polar and nonpolar interactions
with α1, α5 and α6 of the DH domain. This region of the DH domain is the conserved surface
that is responsible for binding to the switch regions of nucleotide-free Rho GTPases, as required
for their activation by catalyzed guanine nucleotide exchange10. Therefore, in this form, the
SH3 domain would block access of CDC42 to the DH domain of ASEF, providing the structural
basis for the autoinhibition of ASEF by its SH3 domain as described above. Important
interactions are also observed between the SH3 domain and the PH domain, occurring between
the RT loop of the SH3 domain and β1 and β2 of the PH domain and between the β3-β4 loop
of the SH3 domain and αC of the PH domain. Helix α6 of the DH domain is extended and
similar in length to α6 in ITSN and Tiam1 (refs. 10,14) but adopts a unique arched conformation
not observed in other DH domains. The arch allows α6 to conform to the surface of the SH3
domain, and this configuration is stabilized by the extensive interactions between the SH3
domain, α6 and the PH domain. This arrangement suggests that in the absence of the SH3
domain—for example, in truncated variants or upon movement of the domain by engagement
of APC—α6 will adopt an alternative conformation.
Although the SH3 domain of ASEF forms a unique interface with DH and PH domains that is
distinct from those observed between other SH3 domains and polyproline (PXXP)-containing
peptides, the PXXP recognition surface is partially occluded (see Supplementary Fig. 4 online).
Therefore, in the observed orientation, the binding of PXXP sequences to the SH3 domain
remains energetically unfavorable. An in-depth description of the PXXP-binding site of ASEF
is available in the Supplementary Data and Supplementary Discussion online.
Comparison of ASEF with collybistin DH/PH–CDC42
Collybistin is a Dbl-family RhoGEF that specifically activates CDC42 (ref. 6) and is highly
similar to ASEF; their respective DH and PH domains are 68% identical. A recent structure
encompassing the DH/PH cassette of collybistin bound to nucleotide-depleted CDC42 (ref.
Mitin et al. Page 5













28) highlights considerable repositioning of the α6 helix of its DH domain, relative to the
structure of ASEF described here (Fig. 6b). In free ASEF, α6 curves toward the main body of
the DH domain and is secured in this conformation by the SH3 domain. Modeling CDC42
from the structure of collybistin–CDC42 onto the GTPase-binding site of ASEF reveals that
the DH and PH domains of ASEF would prohibit CDC42 binding and exchange irrespective
of the SH3 domain. In this inhibited conformation, α6 would impinge upon switch 2 of CDC42,
and regions in the PH domain would clash with α3a, α3b and α4 of CDC42. To relieve this
steric clash, the DH and PH domains of ASEF must adopt a more open conformation, probably
one similar to that observed in collybistin–CDC42. In doing so, α6 must rotate ~45°, to a
position more parallel to the main body of the DH domain, to facilitate an ~30-Å translation
of the PH domain. Molecular dynamics simulations of ASEF have also suggested
conformational flexibility between the DH and PH domains29. Additionally, in the structure
of collybistin–CDC42, the region on the C-terminal side of αC (αC extension) becomes ordered
and packs against the C terminus of αC, presumably to stabilize this conformation. Although
the ASEF ΔABR2 construct used for crystallization encompasses the equivalent αC extension,
electron density in this region is missing from the structure.
From these observations, a mechanism of ASEF activation emerges in which binding of the
ABR of ASEF by APC retracts the SH3 domain from the DH and PH domains, allowing the
GEF to relax into an open and active conformation. Previously determined structures of DH
and PH domains have intimated plasticity of α6, especially in the DH and PH domains of Sos1
(ref. 30). The present comparison of ASEF and collybistin structures reveals large domain
rearrangements of DH/PH cassettes required for regulating the autoinhibition and subsequent
activation of Dbl-family GEFs.
Interface of the SH3 domain with the DH and PH domains
The DH and PH domains of ASEF form an arch stabilized at its center by the SH3 domain
(Fig. 7a). Two sets of hydrophobic interactions in the crown of the arch are crucial for
stabilizing the interface. Chief among these are the interactions of Trp203 at the base of the
RT loop of the SH3 domain, which act as the keystone by packing into a central hydrophobic
pocket formed by residues in α5 and α6 of the DH domain. A hydrogen bond between the
indole nitrogen of Trp203 and the sulfhydryl group of Cys428 cements the interactions. Also
within the RT loop, Met208 inserts into a second hydrophobic pocket framed by residues from
α6 of the DH domain and β1 and β2 of the PH domain, and these interactions seem to be crucial
for maintenance of the arched conformation of the DH and PH domains. In between Trp203
and Met208 of the RT loop, Asp204 forms hydrogen bonds with the side chain of Asn466
within α6, and the backbone oxygen of Val206 interacts with the side chain of Lys477 to further
stabilize the arch. Asn466 is highly conserved in DH domains, where it is required to bind
switch 2 of Rho GTPases during nucleotide exchange5; thus, its central position within the
interface with the SH3 domain emphasizes the overlap between binding sites in the DH domain
for the SH3 domain and for CDC42.
Bracketing Trp203 and Met208 are sets of hydrophilic interactions that further stabilize the
arched conformation of the DH and PH domains. For instance, Asp210 in the RT loop forms
a salt bridge with Lys533 in β3 of the PH domain, and Asp238 in the β3–β4 loop of the SH3
domain binds Arg596 in αC of the PH domain. On the opposite end of the arch and juxtaposed
to the ABR, a network of hydrogen bonds centered on Glu436 in α5 of the DH domain stabilizes
this portion of the interface. Arg249 in β5 of the SH3 domain is particularly important; its side
chain inserts between Glu436 and Glu291 in α1 to form an electrostatic bridge between the
three residues. Of note, Glu291 is also crucial to the GEF activity of DH domains, as it is
needed to form conserved interactions with switch 1 of Rho GTPases5. In addition to
interactions with Arg249, Glu436 also forms hydrogen bonds to the backbone atoms of Val252
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and Asn253, on the C-terminal side of β5 of the SH3 domain. The side chain of Asn253 forms
important interactions with the side chain of Asn287 in α1 of the DH domain to secure this end
of the interface. Because this network of hydrophilic interactions is adjacent to the CAB region
within the ABR, we suggest that these interactions are the first to be disrupted upon APC
binding and that this disruption is followed by ‘unzipping’ of the remainder of the interface to
activate ASEF.
We mutated residues in the SH3 domain that interact with the DH and PH domains of ASEF
to alanines, with the anticipation that disrupting this interface might relieve the autoinhibition
of ASEF. Individual substitutions were made in the background of fully inhibited ASEF
ΔABR2, and mutant proteins were tested for GEF activity in vitro (Fig. 7b). Mutation of
residues that form interactions with the main body of the DH domain (Trp203, Arg249 and
Asn253) were most effective at relieving inhibition, especially W203A, which restored the full
GEF activity of ASEF toward CDC42 in vitro. The equivalent mutation (W156A) in ASEF2
ΔN is also activating (Fig. 7b, right graph), indicating that ASEF and ASEF2 are similarly
auto-inhibited by their respective SH3 domains. Consistent with these in vitro results, ASEF
ΔABR4 W203A and a constitutively active ASEF DH/PH protein induced filopodia formation
to a similar degree in NIH3T3 cells (Fig. 7c).
ASEF is a candidate tumor suppressor
To better understand the regulation of ASEF by APC in CRCs, we suppressed the expression
of ASEF by RNA interference in CRC cell lines that retain full-length (SW48 and HCT116)
or truncated (SW480) APC31,32 and assessed CDC42 activation and tumorigenic potential. We
established individual cell lines stably expressing each of two independent short hairpin RNAs
(shRNA-1 and shRNA-2) targeting ASEF or a nontargeting control (shRNA-C) and assessed
the amount of GTP-bound CDC42 by affinity precipitation. Knockdown of ASEF messenger
RNA in SW48 and HCT116 cell lines harboring full-length APC led to decreased levels of
CDC42-GTP (Fig. 8a). In contrast, the amount of CDC42-GTP remained unchanged in SW480
cells despite depletion of ASEF mRNA.
The HCT116 and SW480 cell lines expressing shRNAs were also assessed for anchorage-
independent growth in soft agar (Fig. 8b; SW48 cells grow poorly in soft agar). HCT116 cells
expressing ASEF-specific shRNAs showed a two- to four-fold increase in anchorage-
independent growth compared to cells expressing control shRNA, whereas colony growth of
SW480 cells was not affected by ASEF knockdown. Notably, in both cell types, anchorage-
independent growth was promoted by expression of a dominant-negative form of CDC42 fused
to a hemag-glutinin tag (HA–CDC42 17N), which forms a nonproductive complex with
CDC42-specific GEFs and suppresses their activity33. These data suggest that full-length APC
promotes the activation of CDC42 by ASEF to suppress the anchorage-independent growth of
HCT116 cells. In SW480 cells expressing truncated APC that does not activate ASEF, CDC42-
GTP levels remained high and no enhancement of anchorage-independent growth was
observed upon ASEF knockdown.
ASEF has recently been found to be mutated in human cancers34 and designated as a candidate
cancer gene predicted to have higher-than-background mutation frequencies in cancers. Two
separate missense mutations of ASEF have been uncovered in breast cancers: K100R in the N
terminus and T441R in the DH domain. In our structure of ASEF, Thr441 resides in the turn
separating α5 and α6, where it participates in an extensive network of hydrogen bonds with
residues in α1, α3, α5 and α6 to stabilize the DH domain fold (Fig. 8c). Substitution of arginine
for Thr441 would disrupt these interactions and would probably be very detrimental to the
overall fold and associated exchange activity of the DH domain. Consistent with this
assumption, T441R mutation in the constitutively active ASEF DH/PH protein abolished its
ability to promote ruffling in COS-7 cells and abolished the activation of ASEF ΔABR2 by
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APCArm in fluorescence-based GEF assays (Fig. 8d). Therefore, we conclude that the T441R
mutation in ASEF causes loss of the GEF activity of ASEF and thereby leads to loss of
regulation of CDC42 by APC. Together, these data imply that loss of ASEF function is
advantageous to tumor progression and that ASEF acts as a tumor suppressor.
DISCUSSION
There are approximately 70 Dbl-family RhoGEFs that differentially activate 20 Rho GTPases
in humans. Although the ASEF-related GEFs collybistin6,28 and ASEF2 (ref. 7) are specific
for CDC42, the specificity of ASEF for Rho GTPases has been controversial. Initial reports
indicated that ASEF was a RAC1-specific GEF8,9,29, whereas a recent study18 showed that
ASEF was specific for CDC42 and not RAC1. Consistent with that study, our data demonstrate
that ASEF acts as a CDC42 GEF in vitro and in vivo and does not activate other Rho GTPases.
Notably, knockdown of ASEF in CRC cell lines expressing full-length APC decreases the
levels of GTP-bound CDC42. This clarification of ASEF specificity is biologically relevant,
as RAC1 and CDC42 regulate distinct cellular processes35.
The structure of autoinhibited ASEF reveals that the SH3 domain forms a unique interface with
regions in both the DH and PH domains and masks the surface on the DH domain (α1, α5 and
α6) required for binding Rho GTPases during nucleotide exchange. This steric occlusion
inhibits the GEF activity of ASEF. The CAB motif and the remainder of the ABR are largely
solvent exposed and not part of the inhibitory interface. Therefore, truncated forms of ASEF
that lack the ABR but retain the SH3 domain are constitutively inhibited, and previous studies
that have used such forms of ASEF and assumed their constitutive activation should be
reinterpreted. Mutations in the SH3 domain (R249A and N253A) that enhance the exchange
activity of full-length ASEF without perturbing the capacity of the SH3 domain to bind
polyproline-containing ligands could be used in place of truncated forms of ASEF in future
studies.
Recently, a different mechanism for ASEF2 autoinhibition has been put forth, in which
interactions between the ABR and SH3 domains and regions on the C-terminal side of the PH
domain are important for its autoinhibition7. However, for both ASEF and ASEF2, we find
that removal of the C-terminal region following the PH domain does not influence the exchange
potential of these GEFs (see Supplementary Fig. 5 online). Furthermore, substitutions in the
SH3 domain of ASEF designed to disrupt its interaction with the DH and PH domains, as well
as analogous substitutions in ASEF2, activate the respective exchange potentials of these GEFs,
indicating that our proposed mechanism of autoinhibition of ASEF is almost certainly
conserved in ASEF2.
It is becoming clear that APC is involved in the regulation of several cellular processes
independent of its role in Wnt signaling, including the reorganization and stabilization of the
cytoskeleton and regulation of cell migration, cell division and apoptosis4. It is increasingly
appreciated that truncated forms of APC associated with cancers might have differential
activities that promote tumorigenesis independently of the loss of β-catenin regulation. ASEF
is reported to have a crucial role in cellular migration downstream of truncated APC9. We show
here that truncation of APC leads to the loss of ASEF function. Truncated APC does not
promote morphological changes associated with ASEF and CDC42 activation, probably owing
to the altered cellular localization of truncated APC. The coupling of APC to CDC42 activation
via ASEF that we observed in CRC cell lines expressing full-length APC is lost upon APC
truncation. Moreover, suppression of ASEF in CRC cells expressing full-length APC greatly
increases anchorage-independent growth of these cells, whereas colony growth is not affected
by ASEF knockdown in cells expressing truncated APC. These data support a mechanism in
which ASEF signals downstream of full-length APC to activate CDC42 to suppress anchorage-
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independent growth. Notably, dominant-negative CDC42 enhances anchorage-independent
growth of CRC cell lines expressing either full-length or truncated APC, demonstrating that
the general loss of CDC42 activity by sequestration of GEFs can promote CRC.
ASEF has recently been found to be mutated in human breast cancers and not in CRCs34. In
one breast tumor, ASEF acquired a homozygous mutation at codon 441 (T441R)36 that
abolishes catalytic activity (Fig. 8d), suggesting that ASEF acts as a tumor suppressor in breast
epithelial cells. Together with our findings in CRC cell lines, these data strongly imply that
the loss of ASEF function is advantageous to tumor progression in general and that ASEF is
a tumor suppressor in multiple cell types. Given that APC is not typically mutated in breast
cancers, and ASEF mutations have not been found in CRCs, it is possible that loss of ASEF
function can be achieved indirectly through mutation of APC (in CRCs) or by direct mutation
and inactivation of ASEF (in breast cancers). The consequence of regulation of CDC42 by
APC and ASEF and the role of CDC42 itself in cancer progression are not known. Future
studies will determine the signaling pathways mediated by ASEF and uncover the roles of
ASEF and CDC42 in human cancers.
METHODS
Protein expression and purification
His6-tagged ASEF and ASEF2 (human) proteins were expressed in Rosetta BL21(DE3)
Escherichia coli cells. To produce selenomethionine (SeMet)-substituted ASEF ΔABR2 for
structure determination, ASEF ΔABR2 was expressed using the methionine-auxotrophic E.
coli strain B834(DE3) and cultured in L-SeMet–enriched media using methods similar to those
described37. Detailed descriptions of protein expression and purification are available in the
Supplementary Methods. APCArm proteins (human, residues 309–798) were purified exactly
as described for ASEF proteins, except all buffers contained 500 mM NaCl and EDTA was
not included in buffer B.
Human placental CDC42 (residues 1–188; C188S), RAC1 (residues 1–189; C189S) and
RHOA (residues 1–190; C190S) were expressed in E. coli strain BL21(DE3) and purified as
described13. His6-tagged Rho GTPases used in Supplementary Figure 1 were prepared as
described38.
Guanine nucleotide exchange assays
N-methylanthraniloyl (mant)-GTP incorporation into bacterially purified Rho GTPases was
carried out with a Perkin-Elmer LS 55 spectrometer at 20 °C. Exchange-reaction assay mixtures
containing 20 mM Tris (pH 7.5), 100 mM NaCl, 5 mM MgCl2, 1 mM DTT, 5% (v/v) glycerol,
400 nM mant-GTP (Molecular Probes) and 2 µM of the relevant GTPase were prepared and
allowed to equilibrate with continuous stirring. After equilibration, ASEF or ASEF2 proteins
were added at 1 µM, and the relative fluorescence (λemission = 360 nm, λexcitation = 440 nm)
was monitored. For experiments including APCArm, we incubated ASEF or ASEF2 proteins
on ice with APCArm for 10 min before adding them to GEF reactions. The final concentration
of APCArm in GEF reactions was 1 µM.
Immunostaining and fluorescence microscopy
For live-cell microscopy, NIH3T3 and COS-7 cells were plated, transfected and imaged in 35-
mm MatTek culture dishes. Plates were mounted 16–24 h after transfection on a temperature-
controlled heated stage (TempControl 37-2 digital, Carl Zeiss MicroImaging), and live cells
were examined with an inverted laser scanning confocal microscope (Zeiss 510 LSM) using
an oil-immersion ×63 NA 1.4 objective. For studies of mCherry-ASEF colocalization with
GFP-APC, images were captured by sequential scanning with the 488-nM spectral line of an
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argon ion laser and the 543-nM HeNe1 laser and emission filters BP 505–530 (for GFP) and
LP 585 (for mCherry).
For indirect immunofluorescence, NIH3T3 cells were plated and transiently transfected in four-
well Lab-Tek chambered glass coverslides (Nunc). The next day, cells were fixed with 4% (v/
v) paraformaldehyde, permeabilized with 0.2% (v/v) Triton X-100 and stained with Alexa 594–
phalloidin (Molecular Probes). Cells were mounted with FluoroSave (Calbiochem) and
examined with a Zeiss 510 LSM confocal microscope. Digital images were processed and
brightness and contrast adjusted with Adobe Photoshop CS2.
Crystallization of ASEF
SeMet-substituted ASEF ΔABR2 was crystallized by vapor diffusion in sitting drops. Drops
were formed by a 2:1 ratio of protein solution (~9mg ml−1 in buffer B) to reservoir solution
(100 mM HEPES (pH 7), 20% (w/v) PEG 3,350, 200 mM magnesium acetate and 10% (v/v)
glycerol), then equilibrated against 1 ml of reservoir solution at 18 °C. Reproducibility and
crystal quality were generally improved by microcrystal seeding. For data collection at 100 K,
crystals were suspended in a rayon loop (Hampton Research) and snap-frozen by immersion
into liquid nitrogen. Crystals belong to the space group C2, with unit cell dimensions of a =
116.4, b = 80.5, c = 101.5 and β = 104.5°. There are two apparent monomers in the asymmetric
unit. A three-wavelength MAD data set (λ1 = 12,661.14 eV, λ2 = 12,659.14 eV, λ3 = 12,760.14
eV) was collected on a single crystal on the Southeast Regional Collaborative Access Team
(SER-CAT) beamline 22-ID at the Advanced Photon Source of Argonne National Laboratory.
A native data set was subsequently collected at the University of North Carolina X-ray facility
on a single crystal at 100 K using an R-AXIS IV++ area detector and a Rigaku RU-H3R rotating
anode X-ray source equipped with focusing optics. Crystals were produced from native protein
as described for SeMet-substituted ASEF ΔABR2, then incubated in a soaking solution
containing 100 mM HEPES (pH 7), 50% (w/v) PEG 3,350, 200 mM magnesium acetate and
10% (v/v) glycerol. Soaked crystals had unit cell dimensions of a = 100.4, b = 79.9, c = 67.4
and β = 123.0°, with one molecule in the asymmetric unit. All data were processed and scaled
using HKL2000 (ref. 39).
Model building and refinement
The Patterson peak-searching program SHELXD40 and the three-wavelength MAD dataset
were initially used to determine the positions of two sets of eight selenium atoms related by
two-fold noncrystallo-graphic symmetry. The positions of the heavy atom sites were refined
using the CCP4 program MLPHARE41 before phase improvement with solvent flattening,
histogram matching and noncrystallographic symmetry averaging using DM42 The resulting
electron density map was used for initial model building; however, density for the PH domain
was almost entirely missing and further refinement gave poor statistics (Rfree > 35). Data
collected on the native crystal were phased by molecular replacement with the CCP4 program
PHASER43 using the best monomer model that resulted from MAD experiments. The resulting
density map was of high quality and easily interpretable (Supplementary Fig. 3). The structure
of ASEF ΔABR2 was completed using native protein data and iterative cycles of model
building and TLS refinement with COOT44 and the CCP4 program REFMAC45. The final
model has a crystallographic R-value of 21.7% (Rfree = 27.9%) using all data from 15–2.25 Å
(see Table 1) and includes residues 181–254 and 278–611 of ASEF. Electron density was
uninterpretable for residues 170–180 (N terminus), 255–277 (SH3-DH linker) and 612–632
(C terminus) and therefore could not be modeled. Owing to the poor electron density in this
region, residues 561–570 (in the β5–β6 loop of the PH domain) were modeled as glycines. In
the Ramachandran plot, 91.8% of residues are in the most favored regions, 7.3% are in the
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allowed region and 0.8% are in the disallowed region. All molecular graphics were generated
with PyMOL (http://pymol.sourceforge.net).
CDC42 affinity precipitation assays
SW48, SW480 and HCT116 cells stably expressing control or ASEF-specific shRNAs were
lysed in lysis buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 10 mM MgCl2, 1% (v/v) Nonidet
P-40, 0.25% (w/v) sodium deoxycholate and 10% (v/v) glycerol) plus protease inhibitor
cocktail (Roche). Glutathione S-transferase (GST)-PAK RBD (see Acknowledgments)
immobilized on glutathione–Sepharose 4B beads was added to clarified total cell lysates and
incubated at 4 °C for 45 min. Beads were pelleted and washed once with lysis buffer and twice
with wash buffer (25 mM Tris (pH 7.5), 40 mM NaCl, 30 mM MgCl2). Total lysate and affinity-
precipitated lysate samples were subjected to SDS-PAGE and analyzed by western blotting
using CDC42-specific antibodies (Santa Cruz Biotechnology).
Statistical analysis
Data was obtained from three independent experiments done in triplicate and P-values were
calculated using a one-tailed Student’s t-test. Significance for all tests was assumed at P <
0.001 (confidence interval 95%).
Additional methods
A detailed description of expression and RNA interference constructs, maintenance of cell
lines, reverse-transcription PCR and soft-agar assays is available in the Supplementary
Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. ASEF is a GEF specific for CDC42
(a) Primary sequence analysis suggests that ASEF is specific for CDC42. Shown is sequence
alignment of specificity-determining region within select DH domains. GEFs specific for
CDC42 have a leucine (red), whereas RAC1-specific GEFs have an isoleucine (blue), in the
position previously shown to be important for RAC1 selectivity in Tiam1 (Ile1187). (b) ASEF
specifically catalyzes nucleotide exchange on CDC42 but not RAC1 or RHOA. The isolated
DH and PH domains of ASEF were used in fluorescence-based GEF assays that monitor the
incorporation of mant-GTP into recombinant Rho GTPases. The DH/PH domains of Dbs and
Tiam1 were used as positive controls. Arrow indicates time of GEF addition. (c) L421I
mutation in ASEF confers the capacity to activate RAC1 at the expense of CDC42 activation.
WT, wild-type.
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Figure 2. ASEF induces filopodia in NIH3T3 fibroblasts
(a) NIH3T3 fibroblasts were transfected with vectors expressing GFP-tagged, constitutively
active CDC42 or RAC1, or YFP-tagged ASEF DH/PH, and stained with Alexa 594–conjugated
phalloidin to visualize the actin cytoskeleton. (b) Coexpression of the CRIB domain of the
CDC42-specific effector protein N-WASP blocked filopodia formation induced by activated
CDC42 and ASEF. Scale bar, 10 µm.
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Figure 3. ASEF is autoinhibited by the SH3 domain
(a) Left, schematic representations of N-terminal truncation mutants of ASEF used in this
study. Position numbers for ASEF correspond to those published for ARHGEF4 (ref. 17). Right,
5-µg samples of recombinant, bacterially produced ASEF, ASEF2 (residues 92–587, ΔN; 147–
587, ΔABR4) and APCArm (residues 309–798) proteins used in this study were separated by
SDS-PAGE and visualized by staining with Coomassie blue to confirm their purity. MWM,
molecular weight marker. (b) The GEF activity of N-terminal truncation mutants of ASEF
toward CDC42, determined by fluorescence-based GEF assays as in Figure 1b. (c) Deletion
of the SH3 domain is required for ASEF activation. NIH3T3 fibroblasts were transiently
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transfected with constructs expressing YFP alone or YFP-tagged full-length and N-terminally
truncated ASEF mutants and imaged live to visualize filopodia formation. Scale bar, 10 µm.
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Figure 4. Identification of CAP motif in ASEF and ASEF2
(a) Stimulation of ASEF truncation mutants by APCArm. The GEF activity of ASEF stimulated
by APC was determined using fluorescence-based GEF assays as in Figure 1b. (b) Sequence
alignment of the CAB motifs from ASEF and ASEF2. (c) Exchange activity of ASEF2 proteins
toward CDC42 in the presence and absence of APCArm.
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Figure 5. Differential activation of ASEF by full-length and truncated APC
(a) Schematic representations of full-length and truncated human APC. Top, APC contains
oligomerization domain (OD), armadillo-repeat domain (ARM), regions for β-catenin binding
(15-residue repeats) and downregulation (20-residue repeats), sequences for Axin binding
(SAMP repeats), basic domain that interacts directly with microtubules (MT), and EB1-binding
region for indirect association with MTs. Bottom, APC is often mutated within the mutational
cluster region (MCR) in cancers, leading to truncated protein. APC 1061 is a truncated form
of APC that results from a common germline mutation. (b) Activated ASEF and CDC42 induce
similar ruffles in COS-7 cells. COS-7 cells expressing constitutively active RAC1, CDC42 or
ASEF ΔSH3 were imaged live. In each case, the bottom z-section (0.4 µm thick) is shown.
Scale bar, 10 µm. (c) Full-length ASEF is activated by the ARM domain of APC. COS-7 cells
were cotransfected with vectors expressing mCherry alone or mCherry-ASEF (FL or SH3-
containing ΔABR4) and GFP-APCArm (wild-type or ASEF binding–deficient variant N507K)
and imaged live. Arrows indicate that wild-type APCArm is recruited to the plasma membrane
together with FL ASEF. Scale bar, 10 µm. (d) Full-length, but not truncated, APC colocalizes
with ASEF to produce membrane ruffles. COS-7 cells were cotransfected with vectors
expressing mCherry alone or mCherry–FL ASEF and GFP–FL APC (wild-type or N507K
mutant) or GFP–APC 1061 and imaged live. Color inset shows that full-length APC and ASEF
colocalize to puncta that have been previously characterized as tips of microtubules.
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Figure 6. Structure of autoinhibited ASEF
(a) Ribbon diagram of ASEF. The SH3 domain forms an extensive interface with the DH and
PH domains. The core APC-binding motif within the ABR contains a small α-helix (αCAB)
that rests against the n-Src loop of the SH3 domain. Dashed line represents disordered linker
region between the SH3 and DH domains. (b) Comparison of autoinhibited ASEF with
collybistin bound to CDC42. The structure of the collybistin DH and PH domains bound to
CDC42 (PDB 2DFK) was superimposed on the structure of ASEF by aligning their DH
domains. In this conformation, the DH and PH domains of ASEF could not bind CDC42 owing
to steric clash, and large conformational differences are evident between the inhibited (ASEF)
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and activated (collybistin) states. Dashed lines indicate sites of steric clash; S2 is switch 2 in
CDC42.
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Figure 7. Detailed view of the SH3 domain interface
(a) Molecular interactions between the SH3 domain and DH and PH domains of ASEF. Dashed
lines indicate hydrophilic interactions (≤3.2 Å except for Trp203, which interacts at 3.4 Å).
(b) Functional analysis of residues within the SH3 domain interface. Substitutions in the SH3
domain of ASEF ΔABR2 were made to selectively disrupt the inhibitory interface and activate
the GEF activity of ASEF for CDC42 in the absence of APC (inset shows purified mutants on
Coomassie-stained gel; MWM, molecular weight markers). Trp156 in ASEF2 is analogous to
Trp203 in ASEF, and W156A in ASEF2 ΔN similarly activates the GEF activity of ASEF2.
For comparison, exchange reactions in the presence of wild-type GEF (WT) and no GEF (none)
are shown. Arrows point to time of GEF addition to the reactions. (c) ASEF W203A activates
CDC42 in vivo. Cells were imaged live using fluorescent confocal microscopy. Scale bar, 10
µm.
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Figure 8. ASEF is a candidate tumor suppressor
(a) ASEF is essential for CDC42 activation in CRC cells containing full-length APC but not
those with truncated APC. shRNA was used to knock down ASEF expression in CRC cell lines
expressing full-length (SW48 and HCT116) or truncated APC (SW480). CDC42-GTP
abundance was assessed by affinity pull-down assays (see Methods) in cells stably expressing
shRNA-1, shRNA-2 or shRNA-C (control; see text). ASEF knockdown was confirmed by
reverse-transcription PCR (GAPDH was used as a control; bottom gels). (b) ASEF knockdown
promotes anchorage-independent growth of HCT116 but not SW480 cells. Cells stably
expressing control or ASEF-specific shRNAs were assayed for their ability to grow in soft agar.
The HA-tagged dominant-negative mutant HA–CDC42 17N was used as a control. Data from
three independent experiments are presented as the mean number of colonies per field
normalized to the number in an experiment with control shRNA. Error bars represent s.e.m.
***P < 0.001. (c) Structural representation of ASEF T441R, a tumor-associated mutant.
Thr441 participates in a network of hydrogen bonds that stabilize one end of the DH domain
(yellow) of ASEF. When Thr441 is mutated to arginine, this network, as well as hydrophobic
core interactions, are disrupted, and this probably results in the unfolding of the DH domain.
Arg441 was modeled in silico and is shown as sticks with green mesh van der Waals surface.
(d) The T441R mutation inactivates ASEF in vivo and in vitro. Top, COS-7 cells were
transfected with a constitutively active ASEF (mCherry-DH/PH) or T441R mutant and
analyzed as in Figure 5b. Bottom, The T441R mutation inactivates ASEF in vitro. ΔABR2
T441R was inactive in fluorescence-based GEF assays when stimulated with APCArm,
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performed as in Figure 3b. Graph shows results of assays; Coomassie-stained gel shows purity
of mutant construct.
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Table 1
Data collection, phasing and refinement statistics
Native SeMet
Data collection
Space group C2 C2
Cell dimensions
  a, b, c (Å) 100.4,79.9, 67.4 116.4,80.5, 101.5
  α, β, γ (°) 90.0,123.0, 90.0 90.0,104.5, 90.0
Peak Inflection Remote
Wavelength 1.5418 0.97925 0.97936 0.97164
Resolution (Å) 58-2.25 (2.34-2.25) 50-2.20 (2.28-2.20) 50-2.20 (2.28-2.20) 50-2.20 (2.28-2.20)
Rsym 4.1 (41.2) 7.7 (29.8) 7.6 (38.1) 6.8 (47.1)
I / σI 30.2 (3.2) 26.7 (4.9) 25.7 (3.7) 24.4 (2.7)
Completeness (%) 99.1 (97.9) 99.6 (97.4) 99.0 (93.5) 98.0 (86.9)




Rwork / Rfree 21.7 / 27.9
No. atoms
  Protein 3,330
  Water 100
B-factors
  Protein 51.3
  Water 48.2
R.m.s. deviations
  Bond lengths (Å) 0.008
  Bond angles (°) 1.063
X-ray diffraction data were collected from two crystals. Values in parentheses are for the highest-resolution shell.
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